Screener
Bicara Therapeutics BCAX Proceeds From Issuance Initial Public Offering
Proceeds From Issuance Initial Public Offering at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
On September 16, 2024, the Company closed its IPO, through which it issued 20,125,000 shares of common stock with par value of $0.0001 per share and a purchase price of $18.00 per share. The Company raised net proceeds of $332.4 million from the issuance of common stock.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's proceeds from issuance initial public offering?
- Bicara Therapeutics (BCAX) reported proceeds from issuance initial public offering of $332.4M in Q3 2024.
- What does proceeds from issuance initial public offering mean?
- Captures the specific cash proceeds raised through the company's initial public offering of common stock. This metric is essential for evaluating the company's initial capitalization and the resources available to execute its long-term clinical development strategy.
Ask your AI about Bicara Therapeutics's proceeds from issuance initial public offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude